Galmed Pharmaceuticals Ltd (GLMD)

Jun 03, 2025

Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire

Jun 03, 2025

May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com

May 27, 2025

May 27, 2025

Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks

May 27, 2025

May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - Longview News-Journal

May 27, 2025

May 24, 2025

Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World

May 24, 2025

May 23, 2025

Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register

May 23, 2025

May 22, 2025

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 22, 2025

May 22, 2025

Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks

May 22, 2025

May 22, 2025

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

May 22, 2025

May 15, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

May 15, 2025

May 14, 2025

Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks

May 14, 2025

May 14, 2025

Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus

May 14, 2025

May 13, 2025

Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramchol in Treating PSC | GLMD Stock News - GuruFocus

May 13, 2025

May 13, 2025

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - PR Newswire

May 13, 2025

May 10, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 10, 2025

May 08, 2025

Galmed Pharmaceuticals Ltd’s Market Journey: Closing Weak at 1.29, Down -11.64 - DWinneX

May 08, 2025

May 07, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World

May 07, 2025

May 07, 2025

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ By Stocktwits - Investing.com India

May 07, 2025

May 06, 2025

GLMD Advances Cancer Treatment with Promising Aramchol Results | GLMD Stock News - GuruFocus

May 06, 2025

May 06, 2025

GLMD: Galmed's Aramchol Boosts Cancer Drug Efficacy in Early Studies | GLMD Stock News - GuruFocus

May 06, 2025

May 06, 2025

Galmed Pharmaceuticals Unveils Promising Oncology Study Results with Aramchol - TipRanks

May 06, 2025

May 06, 2025

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PR Newswire

May 06, 2025

May 03, 2025

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April - Defense World

May 03, 2025

Apr 30, 2025

Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News

Apr 30, 2025

Apr 29, 2025

Understanding the Risks of Investing in Galmed Pharmaceuticals Ltd (GLMD) - knoxdaily.com

Apr 29, 2025

Apr 29, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World

Apr 29, 2025

Apr 29, 2025

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Apr 29, 2025

Apr 28, 2025

Galmed Pharmaceuticals (GLMD) Collaborates with VCU to Tackle GI Cancer Drug Resistance - GuruFocus

Apr 28, 2025

Apr 28, 2025

GLMD’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 28, 2025

Apr 28, 2025

Understanding GLMD stock ratios for better investment decisions - uspostnews.com

Apr 28, 2025

Apr 28, 2025

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga

Apr 28, 2025

Apr 28, 2025

Is Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Stock Worth Investing In for High Returns? - Marketing Sentinel

Apr 28, 2025

Apr 28, 2025

Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development - Stocks Telegraph

Apr 28, 2025

Apr 28, 2025

Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks

Apr 28, 2025

Apr 28, 2025

Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus

Apr 28, 2025

Apr 28, 2025

Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 17, 2025

Galmed partners with VCU to target drug resistance - The Pharma Letter

Apr 17, 2025

Apr 17, 2025

Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks

Apr 17, 2025

Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com

Apr 17, 2025

Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire

Apr 17, 2025

Apr 15, 2025

Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks

Apr 15, 2025

Apr 15, 2025

Galmed reports key biomarkers for heart and liver health - Investing.com

Apr 15, 2025

Apr 15, 2025

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Kilgore News Herald

Apr 15, 2025

Apr 10, 2025

Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks

Apr 10, 2025